PADI4 and rheumatoid arthritis: These polymorphisms are of particular interest for the pathogenesis of RA since PADI4 and other PADI enzymes catalyze change from peptidylarginine to peptidylcitrulline, a target of anti-citrullinated protein antibody (ACPA), through a post-translational modification process referred to as citrullination [13,14].